221 related articles for article (PubMed ID: 29957874)
1. GeneExpressScore Signature: a robust prognostic and predictive classifier in gastric cancer.
Zhu X; Tian X; Sun T; Yu C; Cao Y; Yan T; Shen C; Lin Y; Fang JY; Hong J; Chen H
Mol Oncol; 2018 Nov; 12(11):1871-1883. PubMed ID: 29957874
[TBL] [Abstract][Full Text] [Related]
2. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
[TBL] [Abstract][Full Text] [Related]
3. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.
Ma B; Li Y; Ren Y
Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579
[TBL] [Abstract][Full Text] [Related]
4. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
[TBL] [Abstract][Full Text] [Related]
5. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
Front Immunol; 2021; 12():651033. PubMed ID: 34054812
[TBL] [Abstract][Full Text] [Related]
6. A prognostic 3-long noncoding RNA signature for patients with gastric cancer.
Cheng P
J Cell Biochem; 2018 Nov; 119(11):9261-9269. PubMed ID: 30074647
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.
Zhang F; Maswikiti EP; Wei Y; Wu W; Li Y
Dis Markers; 2021; 2021():5567392. PubMed ID: 34422135
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
10. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
[TBL] [Abstract][Full Text] [Related]
11. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
12. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.
Yan H; Chen Y; Yang Z; Li Z; Che X; Xiao J; Liu Y; Qu X
Front Immunol; 2020; 11():621623. PubMed ID: 33613554
[TBL] [Abstract][Full Text] [Related]
13. Progressive and Prognostic Performance of an Extracellular Matrix-Receptor Interaction Signature in Gastric Cancer.
Yang X; Chen L; Mao Y; Hu Z; He M
Dis Markers; 2020; 2020():8816070. PubMed ID: 33178362
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
15. Establishing a cancer driver gene signature-based risk model for predicting the prognoses of gastric cancer patients.
Chen J; Zhou C; Liu Y
Aging (Albany NY); 2022 Mar; 14(5):2383-2399. PubMed ID: 35288483
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses.
Lou S; Meng F; Yin X; Zhang Y; Han B; Xue Y
Front Immunol; 2021; 12():719628. PubMed ID: 34413861
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Four-Gene-Based SERM Signature for Prognostic and Drug Sensitivity Prediction in Gastric Cancer.
Jia X; Chen B; Li Z; Huang S; Chen S; Zhou R; Feng W; Zhu H; Zhu X
Front Oncol; 2021; 11():799223. PubMed ID: 35096599
[TBL] [Abstract][Full Text] [Related]
18. A nine-consensus-prognostic -gene-based prognostic signature, recognizing the dichotomized subgroups of gastric cancer patients with different clinical outcomes and therapeutic strategies.
Ji D; Yang Y; Zhou F; Li C
Front Genet; 2022; 13():909175. PubMed ID: 36226177
[No Abstract] [Full Text] [Related]
19. A 21‑gene Support Vector Machine classifier and a 10‑gene risk score system constructed for patients with gastric cancer.
Jiang H; Gu J; Du J; Qi X; Qian C; Fei B
Mol Med Rep; 2020 Jan; 21(1):347-359. PubMed ID: 31939629
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and Predictive Value of a Long Non-coding RNA Signature in Glioma: A lncRNA Expression Analysis.
Pan YB; Zhu Y; Zhang QW; Zhang CH; Shao A; Zhang J
Front Oncol; 2020; 10():1057. PubMed ID: 32793467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
